IntelGenx Corp and Cary Pharmaceuticals Inc announced that a New Drug Application has been submitted to the US FDA for their antidepressant CPI-300, a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder (MDD).
the details can be read here.
No comments:
Post a Comment